证券日报网讯 9月1日晚间，华仁药业发布公告称，近日，公司全资子公司安徽恒星制药有限公司收到 国家药品监督管理局核准签发的"盐酸奈福泮"《化学原料药上市申请批准通知书》。 （文章来源：证券日报） ...

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its subsidiary Anhui Hengxing Pharmaceutical to market "Nefopam Hydrochloride," a non-narcotic, non-addictive analgesic drug [1] Group 1: Product Approval - Anhui Hengxing Pharmaceutical has been granted the "Chemical Raw Material Drug Marketing Application Approval Notice" for Nefopam Hydrochloride, with notification number 2025YS00762 [1] Group 2: Product Characteristics - Nefopam Hydrochloride is a powerful analgesic with mild antipyretic and muscle relaxant effects, primarily used for treating acute pain, especially postoperative pain [1] - The drug can also serve as an adjunct in local anesthesia and needle anesthesia [1] - It is not classified as a psychoactive analgesic, thus eliminating concerns regarding addiction [1] Group 3: Clinical Usage - Nefopam Hydrochloride has been widely used in clinical settings for severe pain due to its effective pain relief, minimal side effects, and characteristics of rapid onset and prolonged action [1]